Conflict of Interest

1. Davies L, Welch HG. Current thyroid cancer trends in the united states. JAMA Otolaryngol. Head Neck Surg. 2014; 140; 317– 322. 2. Howitt BE, Jia Y, Sholl LM, Barletta JA. Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid 2013; 23; 1256– 1262. 3. Liu J, Singh B, Tallini G et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 2006; 107; 1255–1264. 4. Rivera M, Ricarte-Filho J, Knauf J et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod. Pathol. 2010; 23; 1191–1200. 5. Vivero M, Kraft S, Barletta JA. Risk stratification of follicular variant of papillary thyroid carcinoma. Thyroid 2013; 23; 273–279. 6. Lim JY, Hong SW, Lee YS et al. Clinicopathologic implications of the BRAF (V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid 2013; 23; 1423–1430. 7. Xing M, Alzahrani AS, Carson KA et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309; 1493–1501. 8. Koperek O, Kornauth C, Capper D et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am. J. Surg. Pathol. 2012; 36; 844–850. 9. Lee SR, Jung CK, Kim TE et al. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing. Thyroid 2013; 23; 1416–1422. 10. Rosai J. Papillary thyroid carcinoma: a root-and-branch rethink. Am. J. Clin. Pathol. 2008; 130; 683–686.